Taisho Pharmaceutical Holdings Co., Ltd.
TAIPY · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $84 | $82 | $81 | $74 |
| % Growth | 1.6% | 1.8% | 9.6% | – |
| Cost of Goods Sold | $37 | $35 | $33 | $32 |
| Gross Profit | $46 | $47 | $48 | $41 |
| % Margin | 55.6% | 57% | 59.8% | 56.3% |
| R&D Expenses | $0 | $5 | $5 | $6 |
| G&A Expenses | $0 | $0 | $0 | -$14 |
| SG&A Expenses | $44 | $35 | $34 | $35 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $49 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $44 | $40 | $39 | $42 |
| Operating Income | $3 | $7 | $9 | -$0 |
| % Margin | 3.2% | 8.9% | 11.2% | -0.1% |
| Other Income/Exp. Net | $2 | -$1 | -$2 | -$0 |
| Pre-Tax Income | $4 | $6 | $7 | -$0 |
| Tax Expense | $1 | $2 | $2 | $1 |
| Net Income | $3 | $3 | $4 | -$2 |
| % Margin | 3.4% | 3.8% | 5.4% | -2.6% |
| EPS | 35.05 | 37.66 | 53.22 | -23.2 |
| % Growth | -6.9% | -29.2% | 329.4% | – |
| EPS Diluted | 35 | 37.6 | 53.15 | -23.2 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $7 | $7 |
| EBITDA | $5 | $7 | $14 | $6 |
| % Margin | 5.4% | 8.2% | 17.4% | 8.6% |